Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ECTE registration revoked:
https://www.sec.gov/litigation/opinions/2021/34-92889.pdf
ECTE registration revoked:
https://www.sec.gov/litigation/opinions/2021/34-92889.pdf
ECTE SEC Suspension for severely delinquent Financials:
https://www.sec.gov/litigation/suspensions/2021/34-91929.pdf
Order:
https://www.sec.gov/litigation/suspensions/2021/34-91929-o.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2021/34-91928.pdf
Somebody market buy my limit sell shares at $1.00 hehe
Are you smoking crack.ECTE has 0 money, no officers, no office, no telephone number, no CGM. Good luck trading among yourselves.
Grabbed a few 2s earlier! Let’s see your monster run here at $ECTE
$ECTE: PAUL on the bid.... just like with COWPP yesterday
You know what that means.
When these guys buy.... they buy big and buy non-stop.
Looking for a move easily to $0.20 from here
Now at $0.02
GO $ECTE
$ECTE: Lets see it move to $0.08
Cuz... there is nothing really in its way.
Up again now to $0.0099
GO $ECTE
$ECTE: Hello hello hello hello hello... Echo echo echo
WOAahhhhhhhhhhhhhhhhhhhhhh
Lets go baby !
Wanna roll like $ONPH and $DCGD !
GO $ECTE
I agree she can DEFINITELY at least make a run to 25 cents with this FLOAT. 13 million O/S????!! WHAT!!?? #BIOTECH??!!
ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE
$ECTE: SHhhhhhhhhhhhhhhhhhhh......... but this is about to POP
Super duper hard back to $0.50
GO $ECTE
ECTE FELLAS ECTE!!
ECTE it's time. 0049? 13 million O/S? Like SERIOUSLY???? LMFAAAAAOOOO. Free money
ECTE shhhhhhhhh about to coast. FLOAT LOCKDOWN
ECTE don't miss this EASY RUN coming up
$ECTE Worldwide Business w/Kathy Ireland segment spotlighting Echo Therapeutics CGM system: https://t.co/m6n4kTXj4R
ECTE TOO EASY AT THIS PRICE
ECTE ready again my friend
$ECTE New CGM wireless, needle-free technology vs. older needle-based CGM sensors: https://t.co/gI9qVy2h9X
ECTE is about to take a flight. ONLY 13 million O/S? Do traders even understand what this means? Understand the significance? Shouldn't be below 4 cents ...ON THE BID with such a FLOAT and INDUSTRY/sector. #BIOTECH!!!!!! People acting like they're out of business, EVEN AS A SHELL shouldn't have subs on the bid. WATCH ME GET THE WORD OUT. Simple math. Float locked here, like REALLY LOCKED not a share out there to be given away at this price, simple math count the shares. Their product is still unique, BUYOUT possibilities still lucrative for whichever BIOTECH company that swings the bat. It's a foriegn company and filed a 13d so information is very limited but their website still putting info in 2019
REMEMBER THE PRODUCT. I've never seen a #BIOTECH with only 13 million O/S sitting with subs on the ask, these guys suck at marketing but I'm gonna at the very least get the word out. So thin $300 bucks moves it lol. Fasten your seatbelts.
$ECTE New CGM wireless, needle-free technology vs. older needle-based CGM sensors: https://t.co/gI9qVy2h9X
ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE ECTE
$ECTE 13 MILLION O/S at 0049? UNBELIEVABLE
$ECTE: Gathering steam now.... Low Floater on watch
Not much talk until this volume just showed up yesterday.
GO $ECTE
Share Count as of 12/07/2018
Authorized Shares 150,000,000
Outstanding Shares 13,297,278
Restricted 1,422,978
Unrestricted 11,874,300
Market Cap $9,308 LOL!!
52-Wk Range
0.0005 - 0.0112
https://www.linkedin.com/company/echo-therapeutics/
http://echotx.com/
https://www.otcmarkets.com/stock/ECTE/profile
@Anonymouse1
Definitely not the same people. Funny though!
As you mention the website is down. Went to a BBQ over the weekend and someone at TUV, a company in the same building as ECTE, mentioned that the ECTE office was locked up some time ago due to non-payment.
On another note, I took @Ramad's advice and invested in XRP when it was at .45. The road looks pretty paved from here. Thanks for throwing that info out there. Hopefully it stays course.
-LT
Alan is not actually Alan. Well, his fake identification may say Alan but he's really either Christopher Robert Metsos or Craig John Oliver. Just check the FBI Most Wanted!!!!!
He also may be both of those men. He's also a black belt in karate which is just fucking cool.
ECTE website down. About time! What a short opportunity! Sorry if y'all lost $$$.
@No_Easy_Money,
I'm no expert, but I agree with what you said.
Going NASDAQ is expensive. You would have to be "certain you had something to bring to market and go primetime".
As we saw with ECTE, going to OTC gave them a sandbox with their own rules.
@Lintin Nemaura's story should seemingly get interesting by the end of April or May . It seems that they should have CE notification of approval(if approved) by that time assuming it was submitted late January.Its pure conjecture on my part but why not play it safe on otc (as apposed to uplisting to NASDAQ)UNLESS you were really certain you had something to bring to market and go primetime ?
At this point Echo's IP could be property of noteholder's?
@No Easy Money,
"Did Echo actually have fda approval for any generation of cgm to be actually commercialized?"
mmmm.....Nope. Everyone would have already known this. In the real world, if company XYZ has a product already fda approved, stock would have have reflected this. Also, a larger company would have bought out said company.
But for sure, that IP is going to be worth some $$$ if Nemaura is able to disrupt the current CGM business.
When Abbott got FDA approval for their Libre, we tested it in house and they have a very good sensor(gen 2). Abbott started purchasing Advertisment (radio/internet/tv) attacking Dexcom stating that their CGM product "Kills people in their sleep". Abbott is also banking on the fact that they are 0 calibration(after 12 hours of warming). Obviously Dexcom and Abbott are at a battle for the space.
If Nemaura comes out with a NI-CGM, someone is going to be interested. (either to hop on board or kill it). I wouldn't be surprised that Dexcom will pair with Abbott legally and defend the invasive market and just block their sales. Who knows... capitalism is a battlefield. Buy a couple years before they are able to cook something up.
@Lintin . This is true . Certainly a successful non invasive cgm would greatly lift Echo IP and make it pretty attractive. Did Echo actually have fda approval for any generation of cgm to be actually commercialized?
interesting....
That does put Alan in an interesting position. If there is a non-invasive CGM out there, then the IP from Echo is of value if a competitor wants to go non-invasive as well.
@Lintin Not a word but their website still up and Alan is still listed with phone# I can't imagine Echo pulling off a miracle especially with Nemaura uplisting to NASDAQ and apparently waiting on CE approval now for their cgm
Anyone know where Echo stands? Where is the tech/ip now? No info from my sources. It's been dead silent.
....May sell my shares just to write off in taxes for next year.
@Ramad
Whats the outlook for the ripple? I've been tracking for some time and there was great traction up until South Korean banned it. I was thinking crypto to recover from Echo.
They never had a cgm or drug delivery system with fda approval that was even close to ready for primetime, it's the only logical explanation I can think of.
I played ECTE way back..Got in @ .23 ,went to the BIG boards went to $3.00, was a Great play....Hard to see it down here in swamp.....Things just did not pan out....Think other BIG companies had a better product, I guess...
It's too far behind the eightball at this point unless someone has been continuing work all this time unannounced or has a boat load of money to look at the carcass and salvage the pieces. Nemaura on the other hand about to go primetime,let's see what happens.
Anybody still hoping for a second coming
Looks like this thing about to have life support unplugged
Have a Happy and Prosperous New Year Ramad !
Wishing everyone a Happy and Prosperous 2018.
For the crypto people Ripple will be the darling for 2018.
No, shorts are covering from very large selling @ the $1.10- $1.20 area. Being Echo has not filed bankruptcy and still trading shorts are covering their positions prior to year end on a steady bases. That's smart money.
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6386
|
Created
|
09/19/04
|
Type
|
Free
|
Moderators |
Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company. Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets.
Echo's AzoneTS™ transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA .
Echo Therapeutics Symphony tCGM Continuous Glucose Monitor
Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system designed to provide reliable, continuous blood glucose data throughout the day and night, improve patient compliance to one-point-in-time glucose testing, and achieve better overall glucose control for people with diabetes and for use in hospital critical care units.
We believe that continuous blood glucose monitoring can be an important part of a diabetes patient's daily disease management program. Continuous blood glucose monitoring can help plan diabetes treatment, guide day-to-day choices about diet, exercise and insulin use, and avoid unwanted low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia) events and the complications that they can cause. Blood glucose levels are affected by many factors such as the carbohydrate and fat content of food, exercise, stress, illness, and variability in insulin absorption among others; therefore, it is often challenging for diabetes patients to avoid frequent and unpredictable excursions above or below normal glucose levels. Patients are often unaware that their glucose levels are either too high or too low, resulting in their inability to tightly control their glucose levels and prevent the complications associated with unwanted glucose excursions.
In an attempt to achieve and maintain blood glucose levels within a desired range, diabetes patients must measure their glucose levels. The ADA recommends that patients test their blood glucose levels at least three or four times per day; however, despite evidence that intensive glucose management reduces the long-term complications associated with diabetes, industry sources estimate that people with diabetes test, on average, less than twice per day. We believe our Symphony tCGM System has the potential to improve patient compliance to frequent glucose testing, achieve better glucose control and make a positive impact on overall day-to-day diabetes management.
We believe Symphony has the potential to offer a non-invasive, wireless, tCGM solution for use in the rapidly emerging hospital critical care market. A primary cause of infection in critically ill patients is hyperglycemia which is a result of insulin resistance and total parenteral nutrition. Clinical studies have demonstrated that intensive insulin therapy to maintain tight glycemic control significantly reduces patient mortality, complications and infection rates, as well as hospital stays, services and overall hospital costs.
Regular monitoring of blood glucose levels is rapidly becoming a necessary procedure performed by hospital critical care personnel to achieve tight glycemic control and ensure improved patient outcomes. In a recent survey by Boston Biomedical Consultants of more than 60 hospital critical care unit managers and nurse clinicians in the United States, more than 90% of those surveyed acknowledged the benefits of tight glycemic control protocols in the hospital critical care setting. We believe tight glycemic control protocols are becoming the new standard of care in hospital critical care units across the United States, for patients with and without diabetes.
Today, standard practice by critical care nurses is to measure blood glucose at the patient's bedside periodically. We believe that a CGM system such as Symphony will save valuable nursing time and expense by avoiding the need for frequent blood glucose sampling, in addition to providing more clinically relevant, real-time glucose level and trending information needed to develop better control algorithms for insulin administration.
Diabetes is a chronic and life-threatening disease caused by the body's inability to produce or properly use insulin, a key hormone the body uses to manage glucose, which fuels the cells in the body. Insulin regulates the uptake of sugar from the blood into the cells. When glucose builds up in the blood instead of going into cells, it can cause the cells to become starved for energy and, over time, damage the eyes, kidneys, nerves or heart. Although not all of the causes of diabetes are known, genetics and lifestyle factors such as obesity and lack of exercise appear to play important roles. According to the American Diabetes Association (ADA), about 21 million people in the United States, or approximately seven percent (7%) of the population, have diabetes, including over 6 million people who remain unaware that they have the disease. In addition, before people develop Type 2 diabetes (discussed below), they usually have "pre-diabetes," or blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. According to the ADA, there are 54 million people in the United States who have pre-diabetes.
When blood glucose levels are high, diabetes patients often administer insulin to reduce their blood glucose level. Unfortunately, insulin administration can reduce blood glucose levels below the normal range, causing hypoglycemia. In cases of severe hypoglycemia, diabetes patients risk severe and acute complications, such as loss of consciousness or death. Due to the drastic nature of acute complications associated with hypoglycemia, many diabetes patients are afraid of sharply reducing their blood glucose levels and often remain in a hyperglycemic state, exposing themselves to long-term complications of that condition.
Diabetes is typically classified into two major groups: Type 1 and Type 2. Type 1 diabetes usually develops in children and young adults and is characterized by the body's inability to produce insulin. People with Type 1 diabetes rely on frequent administration of insulin to regulate their blood glucose levels. Type 2 diabetes, by far the most common form of the disease worldwide, results when either the body does not produce enough insulin or cells in the body ignore the insulin produced and become insulin-resistant. People with Type 2 diabetes often require diet and nutrition management, exercise, oral medications or insulin administration to regulate their blood glucose levels.
According to the ADA, the cost of diabetes care in the United States in 2007 was more than $174 billion, including $116 billion in excess medical expenditures attributed to diabetes and $58 billion in reduced national productivity. The ADA estimates that people with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than the expenditures would be in the absence of diabetes and that approximately $1 in $10 healthcare dollars is attributed to diabetes. A significant portion of overall diabetes care costs, approximately $7 billion according to industry sources, is attributable to costs associated with monitoring blood glucose levels, and that market segment is projected to grow substantially by 2010 as patients and their physicians seek ways to manage glucose levels more effectively.
A 510(k) equivalency study was completed to determine the efficacy of Prelude in enhancing the onset of the effectiveness of 4% lidocaine cream.
A 510(k) premarket notification has been submitted to the US Food and Drug Administration (FDA) for the Prelude SkinPrep System for the delivery of 4% lidocaine cream.
Our Symphony tCGM System is currently in development with an advanced prototype of the Symphony tCGM biosensor. Symphony has successfully completed numerous clinical trials with Symphony and plans additional studies of Symphony in the near future.
Durhalieve is Echo's topical AzoneTS reformulation of triamcinolone acetonide for treatment of corticosteroid-responsive dermatoses. Durhalieve has successfully completed Phase III studies.
Partnerships
Echo is developing its Prelude® SkinPrep System as a platform technology to allow for significantly enhanced skin permeation that will enable needle-free, painless drug delivery as well as analyte extraction. Utilizing the patented, core controlled-feedback skin permeation technology found in Prelude, Echo has initially developed its technology to deliver topical 4% lidocaine cream in a fast-acting, enhanced manner and also to analyze glucose levels continuously using the Symphony® tCGM System.Echo has granted the Ferndale Pharma Group, Inc. and its wholly owned subsidiary Eloquest Healthcare Inc. a license to develop, market and sell the Prelude device for enhanced, fast-acting and needle-free delivery of Ferndale's topical 4% lidocaine product.
The Ferndale Pharma Group of companies specializes in the development, manufacture, distribution and marketing of various dermatologic products including prescription topical drugs for the treatment of several acute and chronic dermatoses, medical devices that support and maintain wound closures, and an extensive line of proprietary cosmeceutical products.
Echo has granted Handok Pharmaceuticals a license to develop, market, and sell Echo's technology to continuously monitor glucose levels, in South Korea. Handok is the leader in diabetes treatment in Korea. Handok maintains a world class GMP facility and was the first local Korean company to incorporate clinical research capabilities with medical directors on staff.
Handok is the leader in diabetes treatment in Korea. Handok, founded in 1954, is the pharmaceutical company in Korea with the most successful track record of various types of partnerships, focusing on innovative products. It formed a JV with Hoechst in 1965, which lead to the current strategic partnership with Sanofi-Aventis. Handok maintains a world class GMP facility and was the first local Korean company to incorporate clinical research capabilities with medical directors on staff.
The partnership is designed to enable close cooperation between the two companies in order to address China's growing demand for both glucose monitoring and transdermal drug delivery solutions. The partnership agreement includes a licensing and technology transfer under which MTIA will undertake regulatory activities, commercialization, and the manufacturing of Echo's technology in China.
Share Structure :
AS ?
OS 12M
Foat 10.88M
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |